Durham, United States
Humacyte is a biotechnology startup based in the United States with a vision to be the global leader in engineering regenerative medicine products to save and improve patient lives. The company is on a mission to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine.
Since its inception in 2004, Humacyte has been developing and manufacturing acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Their flagship product, human acellular vessels (HAVs), has shown promise in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company's endeavors also extend to preclinical development in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications.
Humacyte's $40.20M Post-IPO Equity investment at 29 February 2024, signifies growing investor confidence in the company's disruptive biotechnology platform and its potential to bring about significant advancements in the field of regenerative medicine. As the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and with the HAV technology receiving priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense, Humacyte has demonstrated its potential to make a substantial impact in the medical industry.
For more information, visit www.Humacyte.com.
